Cure My Disease

Don't miss your cure!

 Log in / Sign up

Engineered immune cells take on Hard-to-Treat cancers

NCT ID NCT02869217

Ongoing Disease control Sponsor: University Health Network, Toronto Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-phase trial tests a personalized cell therapy called TBI-1301 for people with advanced solid tumors that express a protein called NY-ESO-1. Patients' own T cells are collected, genetically modified in a lab to better recognize and attack cancer cells, and then infused back. The main goal is to check safety and find the right dose, with a secondary look at whether the treatment shrinks tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
TBI-1301 (genetically modified T cells)
What this could lead to
If it works, this could point toward a treatment for certain advanced solid tumors that express NY-ESO-1.
What could go wrong
This is an early phase 1 trial with only 22 participants, so it is primarily testing safety, not effectiveness. The approach is complex and may not work for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms liver cancer Liver Neoplasms lung cancer lung neoplasm melanoma neoplasm ovarian cancer synovial sarcoma urinary bladder carcinoma Urinary Bladder Neoplasms

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BLADDER CANCER ESOPHAGEAL CANCER LIVER CANCER LUNG CANCER MELANOMA NY-ESO-1 EXPRESSING SOLID TUMORS IN HLA-A2 POSITIVE PATIENTS OVARIAN CANCER SYNOVIAL SARCOMA

Contacts and locations

Locations

  • Princess Margaret Cancer Centre

    Toronto, Ontario, M5G 2M9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.